Advertisement

David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Deborah Collyar: What's In It for Patients?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement

Aug

04

Today In Oncology

FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer

Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL

Advertisement

© 2026 HSP News Service, L.L.C.